PDI inks deal with ‘top-five’ pharma company

PDI has inked a deal with an undisclosed “top-five pharmaceutical company” expected to generate $23 million in revenue for the contract sales firm over its one-year term.

Stephen McGuire

August 1, 2007

4:00 am

PDI has inked a deal with an undisclosed “top-five pharmaceutical company” expected to generate $23 million in revenue for the contract sales firm over its one-year term. PDI said the deal will target primary care physicians and specialty audiences.

From the August 01, 2007 Issue of MM+M - Medical Marketing and Media

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.